GSK: Core EPS up 3% in 2024

(CercleFinance.com) - GSK reports sales of £31,376 million for FY 2024, up 3% (or 7% at constant exchange rates) on the previous year.


Operating profit was £4,021 million, down 40% (-33% at constant exchange rates), with an operating margin of 12.8%, down 8.3 pts at constant exchange rates. Core operating profit was £9148 million, up 4% (+11% at constant exchange rates).

EPS 2024 was 63.2 pence (-40% at constant exchange rates), compared with core EPS of 159.3 pence (+3% as reported, +10% at constant exchange rates).

Emma Walmsley, GSK's Chief Executive Officer, looks forward to a 2024 year of "excellent performance" with "strong growth in sales and core earnings, driven by the acceleration of the specialty medicines portfolio.

This, combined with the remarkable progress of our Phase III pipeline, means that we can look forward to another year of profitable growth in 2025, further enhancing our long-term prospects", she adds.

For 2025, GSK expects sales growth of between 3% and 5%, core operating profit growth of between 6% and 8%, and core EPS growth of between 6% and 8%, including the expected effect of the share buy-back program.

Sales forecasts for 2031 are raised to over £40 billion (previously >£38 billion), reflecting the progress of the late-stage pipeline.

Copyright (c) 2025 CercleFinance.com. All rights reserved.